For example, the development of a scalable and cGMP-compliant autologous organotypic cell therapy for RDEB was recently reported, in which COL7A1 mutation in iPSCs was edited with CRISPR/Cas9 concurrently with their reprogramming into basal keratocytes, dermal fibroblasts, and melanocytes in a single manufacturing step [229]. Here, COL7A1 is linked to recessive dystrophic epidermolysis bullosa.